Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.

@article{Ferreri2015RisktailoredCP,
  title={Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.},
  author={Andr{\'e}s J M Ferreri and Marta Bruno-Ventre and Giovanni Donadoni and Maurilio Ponzoni and Giovanni Citterio and Marco Foppoli and Alessandro Vignati and Lydia Scarfo and Marianna Sassone and Silvia Govi and Federico Caligaris-Cappio},
  journal={British journal of haematology},
  year={2015},
  volume={168 5},
  pages={654-62}
}
The most effective strategy to prevent central nervous system (CNS) dissemination in diffuse large B-cell lymphoma (DLBCL) remains an important, unmet clinical need. Herein, we report a retrospective analysis of risk-tailored CNS prophylaxis in 200 human immunodeficiency virus-negative adults with DLBCL treated with rituximab-CHOP (cyclophosphamide… CONTINUE READING